1. NCHU Institution Repository
  2. 獸醫學院
  3. 獸醫學系所
Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93051
標題: The correlation of molecular phenotypes, chemotherapy response, and prognosis in cats with mammary carcinomas
貓乳腺癌分子表型與化療反應及預後之間的相關性
作者: Ti-Yun Lo
羅禔芸
關鍵字: 貓;免疫組織化學染色;乳腺癌;分子表型;預後;feline;immunohistochemical;mammary;molecular phenotype;prognosis
引用: Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M., 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11, 155-168. Amorim, F.V., Souza, H.J., Ferreira, A.M., Fonseca, A.B., 2006. Clinical, cytological and histopathological evaluation of mammary masses in cats from Rio de Janeiro, Brazil. Journal of Feline Medicine and Surgery 8, 379-388. Arber, D.A., 2002. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Applied Immunohistochemistry & Molecular Morphology 10, 183-186. Archer, S.G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I.O., Blamey, R.W., Nicholson, R.I., Robertson, J.F., 1995. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer 72, 1259-1266. Balleine, R.L., Earl, M.J., Greenberg, M.L., Clarke, C.L., 1999. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. British Journal of Cancer 79, 1564-1571. Bardou, V.J., Arpino, G., Elledge, R.M., Osborne, C.K., Clark, G.M., 2003. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology 21, 1973-1979. Bartsch, R., Wenzel, C., Zielinski, C.C., Steger, G.G., 2007. HER-2-Positive breast cancer - Hope beyond trastummab. Biodrugs 21, 69-77. Bell, D.R., Gerlach, J., Kartner, N., Buick, R., Ling, V., 1985. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. Journal of Clinical Oncology 3, 311-315. Beresford, M.J., Wilson, G.D., Makris, A., 2006. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Research 8, 216. Bergman, P.J., Ogilvie, G.K., Powers, B.E., 1996. Monoclonal Antibody C219 Immunohistochemistry Against P‐Glycoprotein: Sequential Analysis and Predictive Ability in Dogs With Lymphoma. Journal of Veterinary Internal Medicine 10, 354-359. Borrego, J., Cartagena, J., Engel, J., 2009. Treatment of feline mammary tumours using chemotherapy, surgery and a COX‐2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002–2007)*. Veterinary and Comparative Oncology 7, 213-221. Brenn, S.H., Couto, S.S., Craft, D.M., Leung, C., Bergman, P.J., 2008. Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome. Veterinary and Comparative Oncology 6, 201-211. Broxterman, H.J., Giaccone, G., Lankelma, J., 1995. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Current Opinion in Oncology 7, 532-540. Bruno, S., Darzynkiewicz, Z., 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25, 31-40. Burrai, G.P., Mohammed, S.I., Miller, M.A., Marras, V., Pirino, S., Addis, M.F., Uzzau, S., Antuofermo, E., 2010. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor-and progesterone receptor-negative breast lesions. BMC Cancer 10, 156. Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., Karaca, G., Troester, M.A., Tse, C.K., Edmiston, S., Deming, S.L., Geradts, J., Cheang, M.C., Nielsen, T.O., Moorman, P.G., Earp, H.S., Millikan, R.C., 2006. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Journal of the American Medical Association 295, 2492-2502. Castagnaro, M., Casalone, C., Bozzetta, E., De Maria, R., Biolatti, B., Caramelli, M., 1998a. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. Journal of Comparative Pathology 119, 263-275. Castagnaro, M., De Maria, R., Bozzetta, E., Ru, G., Casalone, C., Biolatti, B., Caramelli, M., 1998b. Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Research in Veterinary Science 65, 223-226. Cattoretti, G., Becker, M.H., Key, G., Duchrow, M., Schluter, C., Galle, J., Gerdes, J., 1992. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. The Journal of Pathology 168, 357-363. Chan, H.S., Haddad, G., Thorner, P.S., DeBoer, G., Lin, Y.P., Ondrusek, N., Yeger, H., Ling, V., 1991. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New England Journal of Medicine 325, 1608-1614. Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P.S., Parker, J.S., 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 101, 736-750. Clark, G.M., McGuire, W.L., 1983. Progesterone receptors and human breast cancer. Breast Cancer Research and Treatment 3, 157-163. Clark, G.M., McGuire, W.L., Hubay, C.A., Pearson, O.H., Marshall, J.S., 1983. Progesterone receptors as a prognostic factor in Stage II breast cancer. The New England Journal of Medicine 309, 1343-1347. Cole, S.P., Deeley, R.G., 1998. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20, 931-940. Conneely, O.M., Lydon, J.P., De Mayo, F., O'Malley, B.W., 2000. Reproductive functions of the progesterone receptor. Journal of the Society for Gynecologic Investigation 7, S25-S32. Croop, J.M., Raymond, M., Haber, D., Devault, A., Arceci, R.J., Gros, P., Housman, D.E., 1989. The 3 Mouse Multidrug Resistance (Mdr) Genes Are Expressed in a Tissue-Specific Manner in Normal Mouse-Tissues. Molecular and Cellular Biology 9, 1346-1350. Dahlman-Wright, K., Cavailles, V., Fuqua, S.A., Jordan, V.C., Katzenellenbogen, J.A., Korach, K.S., Maggi, A., Muramatsu, M., Parker, M.G., Gustafsson, J.-Å., 2006. International union of pharmacology. LXIV. Estrogen receptors. Pharmacological Reviews 58, 773-781. De Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M.S., Durbecq, V., Sotiriou, C., Larsimont, D., Piccart-Gebhart, M., Paesmans, M., 2007. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British Journal of Cancer 96, 1504-1513. De Las Mulas, J.M., Van Niel, M., Millan, Y., Ordas, J., Blankenstein, M.A., Van Mil, F., Misdorp, W., 2002. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Research in Veterinary Science 72, 153-161. de las Mulas, J.M.n., Van Niel, M., Millan, Y., Blankenstein, M., van Mil, F., Misdorp, W., 2000. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domestic Animal Endocrinology 18, 111-125. De Maria, R., Olivero, M., Iussich, S., Nakaichi, M., Murata, T., Biolatti, B., Di Renzo, M.F., 2005. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research 65, 907-912. De Potter, C.R., 1994. The neu-oncogene: more than a prognostic indicator? Human Pathology 25, 1264-1268. Dervan, P., Magee, H., Buckley, C., Carney, D., 1992. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. American Journal of Clinical Pathology 97, S21-S28. Dincer, Z., Jasani, B., Haywood, S., Mullins, J., Fuentealba, I., 2001. Metallothionein expression in canine and feline mammary and melanotic tumours. Journal of Comparative Pathology 125, 130-136. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., Walsh, G., 2007. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99, 167-170. du Manoir, S., Guillaud, P., Camus, E., Seigneurin, D., Brugal, G., 1991. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12, 455-463. Egervari, K., Szollosi, Z., Nemes, Z., 2008. Immunohistochemical antibodies in breast cancer HER2 diagnostics. Tumor Biology 29, 18-27. Elston, C.W., Ellis, I.O., 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410. Evans, R.M., 1988. The steroid and thyroid hormone receptor superfamily. Science 240, 889-895. Faratian, D., Munro, A., Twelves, C., Bartlett, J.M., 2009. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 54, 254-257. Gama, A., Alves, A., Schmitt, F., 2008. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Archiv 453, 123-132. Gasparini, G., Pozza, F., Meli, S., Reitano, M., Santini, G., Bevilacqua, P., 1991. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Research 11, 2015-2021. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U., Stein, H., 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology 133, 1710-1715. Gerdes, J., Schwab, U., Lemke, H., Stein, H., 1983. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. International Journal of Cancer 31, 13-20. Giménez, F., Hecht, S., Craig, L.E., Legendre, A.M., 2010. Early detection, aggressive therapy Optimizing the management of feline mammary masses. Journal of Feline Medicine and Surgery 12, 214-224. Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thurlimann, B., Senn, H.J., Panel, m., 2011. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22, 1736-1747. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P., Chambon, P., 1986. Human Estrogen-Receptor Cdna - Sequence, Expression and Homology to V-Erb-A. Nature 320, 134-139. Group, E.B.C.T.C., 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 351, 1451-1467. Haerslev, T., Jacobsen, G.K., Zedeler, K., 1996. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Research and Treatment 37, 101-113. Hahn, K.A., Adams, W.H., 1997. Feline mammary neoplasia: Biological behavior, diagnosis, and treatment alternatives. Feline Practice 25, 5-11. Hamilton, J.M., Else, R.W., Forshaw, P., 1976. Oestrogen receptors in feline mammary carcinomas. The Veterinary Record 99, 477-479. Hayden, D.W., Nielsen, S.W., 1971. Feline mammary tumours. The Journal of Small Animal Practice 12, 687-698. Hayes, A.A., Mooney, S., 1985. Feline mammary tumors. Veterinary Clinics of North America: Small Animal Practice 15, 513-520. Hayes, H.M., Jr., Milne, K.L., Mandell, C.P., 1981. Epidemiological features of feline mammary carcinoma. The Veterinary Record 108, 476-479. Henderson, B.E., Feigelson, H.S., 2000. Hormonal carcinogenesis. Carcinogenesis 21, 427-433. Hifumi, T., Miyoshi, N., Kawaguchi, H., Nomura, K., Yasuda, N., 2010. Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. Journal of Veterinary Medical Science 72, 665-668. Hsu, W.L., Huang, H.M., Liao, J.W., Bong, M.L., Chang, S.C., 2009. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. The Veterinary Journal 180, 116-123. Hu, Z., Fan, C., Oh, D.S., Marron, J., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., 2006. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96. Huggins, C., Moon, R.C., Morii, S., 1962. Extinction of experimental mammary cancer, I. Estradiol-17β and progesterone. Proceedings of the National Academy of Sciences of the United States of America 48, 379. Hughes, K., Dobson, J., 2012. Prognostic histopathological and molecular markers in feline mammary neoplasia. The Veterinary Journal 194, 19-26. Ito, T., Kadosawa, T., Mochizuki, M., Matsunaga, S., Nishimura, R., Sasaki, N., 1996. Prognosis of malignant mammary tumor in 53 cats. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 58, 723-726. Jalava, P., Kuopio, T., Juntti-Patinen, L., Kotkansalo, T., Kronqvist, P., Collan, Y., 2006. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48, 674-682. Jensen, E., DeSombre, E., Jungblut, P., 1967. Estrogen receptors in hormone-responsive tissues and tumors. Endogenous Factors Influencing Host-Tumor Balance, 15-30. Johnston, S.D., Hayden, D.W., Kiang, D.T., Handschin, B., Johnson, K.H., 1984. Progesterone receptors in feline mammary adenocarcinomas. American Journal of Veterinary Research 45, 379-382. Juliano, R., Ling, V., Graves, J., 1976. Drug-Resistant Mutants of Chinese-Hamster Ovary Cells Possess an Altered Cell-Surface Carbohydrate Component. Journal of Supramolecular Structure 4, 521-526. Kartner, N., Ling, V., 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E., Yarden, Y., 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. The EMBO Journal 15, 254-264. Kiessling, R., Wei, W.Z., Herrmann, F., Lindencrona, J.A., Choudhury, A., Kono, K., Seliger, B., 2002. Cellular immunity to the Her-2/neu protooncogene. Advances in Cancer Research 85, 101-144. Klapper, L.N., Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., Yarden, Y., 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the National Academy of Sciences of the United States of America 96, 4995-5000. Klintman, M., Bendahl, P.O., Grabau, D., Lovgren, K., Malmstrom, P., Ferno, M., South Sweden Breast Cancer, G., 2010. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Modern pathology 23, 251-259. Kuiper, G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.-A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the United States of America 93, 5925-5930. Kuiper, G.G., Gustafsson, J.-Å., 1997. The novel estrogen receptor-β subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. Febs Letters 410, 87-90. Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., Gustafsson, J.-A.k., 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139, 4252-4263. Lehne, G., 2000. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Current Drug Targets 1, 85-99. Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., Boisseau, M.R., 1991. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 12, 42-49. Lydon, J.P., DeMayo, F.J., Funk, C.R., Mani, S.K., Hughes, A.R., Montgomery, C.A., Jr., Shyamala, G., Conneely, O.M., O'Malley, B.W., 1995. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes & Development 9, 2266-2278. MacEwen, E., Hayes, A., Harvey, H.J., Patnaik, A., Mooney, S., Passe, S., 1984. Prognostic factors for feline mammary tumors. Journal of the American Veterinary Medical Association 185, 201-204. Maniscalco, L., Iussich, S., de las Mulas, J.M., Millán, Y., Biolatti, B., Sasaki, N., Nakagawa, T., De Maria, R., 2012. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. The Veterinary Journal 191, 65-71. McCormick, G.M., Moon, R.C., 1973. Effect of increasing doses of estrogen and progesterone on mammary carcinogenesis in the rat. European Journal of Cancer 9, 483-486. McNeill, C., Sorenmo, K., Shofer, F., Gibeon, L., Durham, A., Barber, L., Baez, J., Overley, B., 2009. Evaluation of Adjuvant Doxorubicin‐Based Chemotherapy for the Treatment of Feline Mammary Carcinoma. Journal of Veterinary Internal Medicine 23, 123-129. Mealey, K.L., 2004. Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics 27, 257-264. Millanta, F., Calandrella, M., Bari, G., Niccolini, M., Vannozzi, I., Poli, A., 2005a. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Research in Veterinary Science 79, 225-232. Millanta, F., Calandrella, M., Citi, S., Della Santa, D., Poli, A., 2005b. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Veterinary Pathology Online 42, 30-34. Millanta, F., Calandrella, M., Vannozzi, I., Poli, A., 2006. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. The Veterinary Record 158, 821-824. Millanta, F., Lazzeri, G., Mazzei, M., Vannozzi, I., Poli, A., 2002. MIB-1 Labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Veterinary Pathology 39, 120-126. Mills, S.W., Musil, K.M., Davies, J.L., Hendrick, S., Duncan, C., Jackson, M.L., Kidney, B., Philibert, H., Wobeser, B.K., Simko, E., 2015. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Veterinary Pathology 52, 238-249. Misdorp, W., Else, R., Hellmen, E., Lipscomb, T., 1999. Feline. In: Histological Classification of Mammary Tumors of the Dog and the Cat. Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington, pp. 23-29. Misdorp, W., Romijn, A., Hart, A.A., 1991. Feline mammary tumors: a case-control study of hormonal factors. Anticancer Research 11, 1793-1797. Misdorp, W., Weijer, K., 1980. Animal model of human disease: breast cancer. The American Journal of Pathology 98, 573. Morris, J.S., Nixon, C., Bruck, A., Nasir, L., Morgan, I.M., Philbey, A.W., 2008. Immunohistochemical expression of TopBP1 in feline mammary neoplasia in relation to histological grade, Ki67, ERalpha and p53. The Veterinary Journal 175, 218-226. Muggia, F.M., Cassileth, P.A., Ochoa, M., Flatow, F.A., Gellhorn, A., Hyman, G.A., 1968. Treatment of breast cancer with medroxyprogesterone acetate. Annals of Internal Medicine 68, 328-337. Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 10, 5367-5374. Novosad, C.A., 2003. Principles of treatment for mammary gland tumors. Clinical Techniques in Small Animal Practice 18, 107-109. Ordás, J., Millán, Y., Dios, R., Reymundo, C., de las Mulas, J.M., 2007. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 7, 179. Overley, B., Shofer, F.S., Goldschmidt, M.H., Sherer, D., Sorenmo, K.U., 2005. Association between ovarihysterectomy and feline mammary carcinoma. Journal of Veterinary Internal Medicine/American College of Veterinary Internal Medicine 19, 560-563. Owen, L.N., 1980. TNM classification of tumours in domestic animals. TNM Classification of Tumours in Domestic Animals. Perou, C.M., Jeffrey, S.S., van de Rijn, M., Rees, C.A., Eisen, M.B., Ross, D.T., Pergamenschikov, A., Williams, C.F., Zhu, S.X., Lee, J.C., Lashkari, D., Shalon, D., Brown, P.O., Botstein, D., 1999. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proceedings of the National Academy of Sciences of the United States of America 96, 9212-9217. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lonning, P.E., Borresen-Dale, A.L., Brown, P.O., Botstein, D., 2000. Molecular portraits of human breast tumours. Nature 406, 747-752. Pinder, S.E., Wencyk, P., Sibbering, D.M., Bell, J.A., Elston, C.W., Nicholson, R., Robertson, J.F., Blamey, R.W., Ellis, I.O., 1995. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. British Journal of Cancer 71, 146-149. Preziosi, R., Sarli, G., Benazzi, C., Mandrioli, L., Marcato, P.S., 2002. Multiparametric survival analysis of histological stage and proliferative activity in feline mammary carcinomas. Research in Veterinary Science 73, 53-60. Rasotto, R., Caliari, D., Castagnaro, M., Zanetti, R., Zappulli, V., 2011. An Immunohistochemical study of HER-2 expression in feline mammary tumours. Journal of Comparative Pathology 144, 170-179. Remmele, W., Stegner, H.E., 1987. A Proposal for the Standardization of the Immunoreactive Score (Irs) for the Immunohistochemical Demonstration of Estrogen-Receptors (Er-Ica) in Breast-Cancer. Pathologe 8, 138-140. Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer Jr, C.E., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353, 1673-1684. Ross, J.S., Fletcher, J.A., 1998. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413-428. Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K.R., Stec, J., Ayers, M., Wagner, P., Morandi, P., Fan, C., Rabiul, I., Ross, J.S., Hortobagyi, G.N., Pusztai, L., 2005. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 11, 5678-5685. Rozan, S., Vincent-Salomon, A., Zafrani, B., Validire, P., De Cremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V., Pouillart, P., Sastre-Garau, X., 1998. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. International Journal of Cancer 79, 27-33. Rutteman, G., Blankenstein, M., Minke, J., Misdorp, W., 1990. Steroid receptors in mammary tumours of the cat. Acta Endocrinologica 125, 32-37. Rutteman, G.R., Withrow, S.J., MacEwen, E.G., 2001. Tumors of the mammary gland, In: Withrow, S.J., MacEwen, E.G. (Eds), Small Animal Clinical Oncology, 3rd ed. WB Saunders Co., Philadelphia, USA, pp. 467-473. S?rlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98, 10869-10874. S?rlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100, 8418-8423. Sahin, A.A., Ro, J., Ro, J.Y., Blick, M.B., el-Naggar, A.K., Ordonez, N.G., Fritsche, H.A., Smith, T.L., Hortobagyi, G.N., Ayala, A.G., 1991. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68, 549-557. Sarli, G., Benazzi, C., Preziosi, R., Della Salda, L., Bettini, G., Marcato, P.S., 1999. Evaluating mitotic activity in canine and feline solid tumors: standardizing the parameter. Biotech Histochem 74, 64-76. Sarli, G., Preziosi, R., Benazzi, C., Bazzo, R., Mandrioli, L., Marcato, P.S., 2003. Rate of apoptosis in feline mammary tumors is not predictive of postsurgical survival. Journal of Veterinary Diagnostic Investigation 15, 115-122. Sato, O., Wada, T., Kawai, A., Yamaguchi, U., Makimoto, A., Kokai, Y., Yamashita, T., Chuman, H., Beppu, Y., Tani, Y., Hasegawa, T., 2005. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas - A clinicopathologic study of 281 cases. Cancer 103, 1881-1890. Sauna, Z.E., Smith, M.M., Muller, M., Kerr, K.M., Ambudkar, S.V., 2001. The mechanism of action of multidrug-resistance-linked P-glycoprotein. Journal of Bioenergetics and Biomembranes 33, 481-491. Schinkel, A.H., 1998. The pharmacological role of P-glycoprotein. Naunyn-Schmiedebergs Archives of Pharmacology 358, R25-R25. Scholzen, T., Gerdes, J., 2000. The Ki-67 protein: from the known and the unknown. Journal of Cellular Physiology 182, 311-322. Seixas, F., Palmeira, C., Pires, M.A., Bento, M.J., Lopes, C., 2011. Grade is an independent prognostic factor for feline mammary carcinomas: A clinicopathological and survival analysis. The Veterinary Journal 187, 65-71. Selvarajan, S., Bay, B.H., Chng, M.J., Tan, P.H., 2004. The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference? Annals of the Academy of Medicine, Singapore 33, 473-476. Slamon, D.J., Clark, G.M., 1988. Amplification of c-erbB-2 and aggressive human breast tumors? Science 240, 1795-1798. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. Sotiriou, C., Neo, S.Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., Martiat, P., Fox, S.B., Harris, A.L., Liu, E.T., 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America 100, 10393-10398. Surowiak, P., Materna, V., Matkowski, R., Szczuraszek, K., Kornafel, J., Wojnar, A., Pudelko, M., Dietel, M., Denkert, C., Zabel, M., 2005. Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Research 7, R862-870. Tanei, T., Shimomura, A., Shimazu, K., Nakayama, T., Kim, S.J., Iwamoto, T., Tamaki, Y., Noguchi, S., 2011. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. European Journal of Cancer 37, 155-161. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C., 1987. Cellular-Localization of the Multidrug-Resistance Gene-Product P-Glycoprotein in Normal Human-Tissues. Proceedings of the National Academy of Sciences of the United States of America 84, 7735-7738. Thomson, T.A., Hayes, M.M., Spinelli, J.J., Hilland, E., Sawrenko, C., Phillips, D., Dupuis, B., Parker, R.L., 2001. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Modern Pathology 14, 1079-1086. Tsai, C.M., Chang, K.T., Wu, L.H., Chen, J.Y., Gazdar, A.F., Mitsudomi, T., Chen, M.H., Perng, R.P., 1996. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Research 56, 206-209. Tzahar, E., Yarden, Y., 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochimica et Biophysica Acta (BBA). Cancer 1377, M25-M37. Untch, M., Gerber, B., Harbeck, N., Jackisch, C., Marschner, N., Mobus, V., von Minckwitz, G., Loibl, S., Beckmann, M.W., Blohmer, J.U., Costa, S.D., Decker, T., Diel, I., Dimpfl, T., Eiermann, W., Fehm, T., Friese, K., Janicke, F., Janni, W., Jonat, W., Kiechle, M., Kohler, U., Luck, H.J., Maass, N., Possinger, K., Rody, A., Scharl, A., Schneeweiss, A., Thomssen, C., Wallwiener, D., Welt, A., 2013. 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care 8, 221-229. Urruticoechea, A., Smith, I.E., Dowsett, M., 2005. Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology 23, 7212-7220. van't Veer, L.J., Dai, H., Van De Vijver, M.J., He, Y.D., Hart, A.A., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536. Van der Heyden, S., Chiers, K., Vercauteren, G., Daminet, S., Wegge, B., Paepe, D., Ducatelle, R., 2011. Expression of multidrug resistance-associated P-glycoprotein in feline tumours. Journal of Comparative Pathology 144, 164-169. Van Diest, P., Van Der Wall, E., Baak, J., 2004. Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology 57, 675-681. Viste, J.R., Myers, S.L., Singh, B., Simko, E., 2002. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. The Canadian Veterinary Journal. La revue Veterinaire Canadienne 43, 33-37. Weijer, K., Hart, A.A., 1983. Prognostic factors in feline mammary carcinoma. Journal of the National Cancer Institute 70, 709-716. Weikel, W., Brumm, C., Wilkens, C., Beck, T., Knapstein, P.G., 1995. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detection and Prevention 19, 446-450. Wiese, D.A., Thaiwong, T., Yuzbasiyan-Gurkan, V., Kiupel, M., 2013. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 13, 403. Winston, J., Craft, D., Scase, T., Bergman, P., 2005. Immunohistochemical detection of HER‐2/neu expression in spontaneous feline mammary tumours. Veterinary and Comparative Oncology 3, 8-15. Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schutz, F., 2008. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research 10, R65. Wu, C.C., Shyu, R.Y., Chou, J.M., Jao, S.W., Chao, P.C., Kang, J.C., Wu, S.T., Huang, S.L., Jiang, S.Y., 2006. RARRES1 expression is significantly related to tumor differentiation and staging in colorectal adenocarcinoma. European Journal of Cancer 42, 557-565. Yue, W., Wang, J.-P., Li, Y., Bocchinfuso, W.P., Korach, K.S., Devanesan, P.D., Rogan, E., Cavalieri, E., Santen, R.J., 2005. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clinical Cancer Research 11, 925s-930s. Zappulli, V., Rasotto, R., Caliari, D., Mainenti, M., Pena, L., Goldschmidt, M.H., Kiupel, M., 2015. Prognostic evaluation of feline mammary carcinomas: a review of the literature. Veterinary Pathology 52, 46-60.
摘要: 
乳腺腫瘤約佔所有貓腫瘤的17%，其中至少有85%為惡性且常見轉移。由於人類乳癌的分子表型與臨床預後有顯著相關。因此本研究利用人類乳癌的分子分型方式將貓乳癌分型並分析其與預後之相關性。病例來自47隻患有乳癌的貓，利用免疫組織化學染色技術分析動情素受器(estrogen receptor, ER)、黃體助孕素受器(progesterone receptor, PR)、人類上皮生長因子受器-2 (human epidermal growth factor receptor-2, HER-2)、Ki-67及P-glycoprotein的表現。由單一因子分析結果可見兩年內ER陽性患貓的存活時間長於ER陰性患貓；PR陽性的乳腺癌多為低分級的腫瘤；HER-2過度表現的乳腺癌多可見區域淋巴結轉移。分子分型之後可見luminal B HER-2 positive、basal-like、和 HER-2過度表現型的乳癌多為高分期的腫瘤。患有luminal B HER-2 positive和basal-like型乳癌的貓比患有luminal A、luminal B HER-2 negative、和HER-2型乳癌的貓有較差的中位存活時間。ER可以做為貓乳癌的預後單一因子，而貓乳癌的分子分型與臨床腫瘤分期有顯著相關性。再者，患有HER-2型乳癌的貓多為高臨床分期的患貓，但其中位存活時間較患有luminal B HER-2 positive或basal-like型的貓較長。因此，貓乳癌分子分型可以做為存活的預後因子之一。

Mammary tumors constitute approximately 17% of all feline neoplasms, and at least 85% are malignant and metastasis is common. Molecular phenotypes of human breast cancers (HBCs) were correlated with prognosis. The aims of this study were to categorize feline mammary carcinoma (FMC) via molecular classification of HBCs and analyze the correlations between phenotypes and prognosis. Mammary carcinomas were obtained from 47 cats. The expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, and P-glycoprotein (P-gp) were detected by immunohistochemical procedures. In two-year follow-up analysis, cats with ER-positive FMC showed significant longer OST than cats with ER-negative FMC. Samples that defined as PR-positive were most likely to be low grade FMC. And FMC over-expressed HER-2 were most likely revealed regional lymph node metastasis. However, when analyzed molecular phenotypes, luminal B HER-2 positive, basal-like, and HER-2 over-expression types were most likely to be high stage FMCs. Cats with luminal B HER-2 positive and basal-like types FMC had worse median survival time than cats with luminal A, luminal B HER-2 negative, and HER-2 type FMC. In conclusion, ER alone can be a prognosis factor of FMC, and molecular phenotype of FMCs showed significant correlation with clinical stage. Moreover, cats with HER-2 type FMC which was most likely to be high clinical stage tend to have longer median survival time than luminal B HER-2 positive or basal-like type FMC. Therefore, molecular phenotype of FMC may be a prognosis factors to survival, which showed difference prognosis to molecular phenotype of HBC.
URI: http://hdl.handle.net/11455/93051
其他識別: U0005-3107201523375500
Rights: 同意授權瀏覽/列印電子全文服務，2016-08-07起公開。
Appears in Collections:獸醫學系所

Files in This Item:
File SizeFormat Existing users please Login
nchu-104-7101038023-1.pdf1.78 MBAdobe PDFThis file is only available in the university internal network   
Show full item record
 
TAIR Related Article

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.